The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor

Yucai Wang, Kari G. Rabe, Michael S. Bold, Min Shi, Curtis A. Hanson, Susan M. Schwager, Timothy G. Call, Saad S. Kenderian, Eli Muchtar, Suzanne R. Hayman, Amber B. Koehler, Amie L. Fonder, Asher A. Chanan-Khan, Daniel L. van Dyke, Susan L. Slager, Neil E. Kay, Wei Ding, Jose F. Leis, Sameer A. Parikh

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Chronic lymphocytic leukemia (CLL) is a low grade B-cell malignancy. Approximately 2-10% of CLL can undergo Richter's transformation (RT) to an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL).1-3 Management of RT is extremely challenging and the clinical outcome is dismal.4 In CLL patients with suspected disease progression, distinguishing between progressive CLL and RT is critically important, as the management and prognosis are different.

Original languageEnglish (US)
JournalHaematologica
Volume105
Issue number5
DOIs
StatePublished - Jan 2020

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'The role of <sup>18</sup>F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor'. Together they form a unique fingerprint.

  • Cite this